181 related articles for article (PubMed ID: 38040120)
1. Long-acting inhaled medicines: Present and future.
Zhang C; D'Angelo D; Buttini F; Yang M
Adv Drug Deliv Rev; 2024 Jan; 204():115146. PubMed ID: 38040120
[TBL] [Abstract][Full Text] [Related]
2. [Standard technical specifications for methacholine chloride (Methacholine) bronchial challenge test (2023)].
; ;
Zhonghua Jie He He Hu Xi Za Zhi; 2024 Feb; 47(2):101-119. PubMed ID: 38309959
[TBL] [Abstract][Full Text] [Related]
3. [Chinese expert consensus on standardized inhaler device application in stable chronic airway diseases (2023)].
Inhalation Therapy and Respiratory Rehabilitation Group, Respiratory Equipment Committee of China Association of Medical Equipment
Zhonghua Jie He He Hu Xi Za Zhi; 2023 Nov; 46(11):1055-1067. PubMed ID: 37914418
[TBL] [Abstract][Full Text] [Related]
4. Drug combinations for inhalation: Current products and future development addressing disease control and patient compliance.
Banat H; Ambrus R; Csóka I
Int J Pharm; 2023 Aug; 643():123070. PubMed ID: 37230369
[TBL] [Abstract][Full Text] [Related]
5. Pharmaceutical strategies to extend pulmonary exposure of inhaled medicines.
Guo Y; Bera H; Shi C; Zhang L; Cun D; Yang M
Acta Pharm Sin B; 2021 Aug; 11(8):2565-2584. PubMed ID: 34522598
[TBL] [Abstract][Full Text] [Related]
6. Inhaled RNA drugs to treat lung diseases: Disease-related cells and nano-bio interactions.
Zhang M; Lu H; Xie L; Liu X; Cun D; Yang M
Adv Drug Deliv Rev; 2023 Dec; 203():115144. PubMed ID: 37995899
[TBL] [Abstract][Full Text] [Related]
7. Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis.
Kew KM; Dias S; Cates CJ
Cochrane Database Syst Rev; 2014 Mar; 2014(3):CD010844. PubMed ID: 24671923
[TBL] [Abstract][Full Text] [Related]
8. Is a long-acting inhaled bronchodilator the first agent to use in stable chronic obstructive pulmonary disease?
Tashkin DP
Curr Opin Pulm Med; 2005 Mar; 11(2):121-8. PubMed ID: 15699783
[TBL] [Abstract][Full Text] [Related]
9. Developments in inhaled combination therapies: patent activity 2013-2014.
Norman P
Expert Opin Ther Pat; 2015; 25(11):1239-45. PubMed ID: 26135360
[TBL] [Abstract][Full Text] [Related]
10. Inhaler technique and training in people with chronic obstructive pulmonary disease and asthma.
Capstick TG; Clifton IJ
Expert Rev Respir Med; 2012 Feb; 6(1):91-101; quiz 102-3. PubMed ID: 22283582
[TBL] [Abstract][Full Text] [Related]
11. Access to affordable medicines and diagnostic tests for asthma and COPD in sub Saharan Africa: the Ugandan perspective.
Kibirige D; Kampiire L; Atuhe D; Mwebaze R; Katagira W; Muttamba W; Nantanda R; Worodria W; Kirenga B
BMC Pulm Med; 2017 Dec; 17(1):179. PubMed ID: 29216852
[TBL] [Abstract][Full Text] [Related]
12. Co-suspension delivery technology in pressurized metered-dose inhalers for multi-drug dosing in the treatment of respiratory diseases.
Ferguson GT; Hickey AJ; Dwivedi S
Respir Med; 2018 Jan; 134():16-23. PubMed ID: 29413503
[TBL] [Abstract][Full Text] [Related]
13. Inhaled Medicines: Past, Present, and Future.
Anderson S; Atkins P; Bäckman P; Cipolla D; Clark A; Daviskas E; Disse B; Entcheva-Dimitrov P; Fuller R; Gonda I; Lundbäck H; Olsson B; Weers J
Pharmacol Rev; 2022 Jan; 74(1):48-118. PubMed ID: 34987088
[TBL] [Abstract][Full Text] [Related]
14. Delivery Technologies for Orally Inhaled Products: an Update.
Moon C; Smyth HDC; Watts AB; Williams RO
AAPS PharmSciTech; 2019 Feb; 20(3):117. PubMed ID: 30783904
[TBL] [Abstract][Full Text] [Related]
15. Use of functional respiratory imaging to characterize the effect of inhalation profile and particle size on lung deposition of inhaled corticosteroid/long-acting β2-agonists delivered via a pressurized metered-dose inhaler.
Van Holsbeke C; De Backer J; Vos W; Marshall J
Ther Adv Respir Dis; 2018; 12():1753466618760948. PubMed ID: 29499614
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature.
Brocklebank D; Ram F; Wright J; Barry P; Cates C; Davies L; Douglas G; Muers M; Smith D; White J
Health Technol Assess; 2001; 5(26):1-149. PubMed ID: 11701099
[TBL] [Abstract][Full Text] [Related]
17. What to consider before prescribing inhaled medications: a pragmatic approach for evaluating the current inhaler landscape.
Lavorini F; Janson C; Braido F; Stratelis G; Løkke A
Ther Adv Respir Dis; 2019; 13():1753466619884532. PubMed ID: 31805823
[TBL] [Abstract][Full Text] [Related]
18. Excipients for Novel Inhaled Dosage Forms: An Overview.
Yousry C; Goyal M; Gupta V
AAPS PharmSciTech; 2024 Feb; 25(2):36. PubMed ID: 38356031
[TBL] [Abstract][Full Text] [Related]
19. Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma.
Kew KM; Dahri K
Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD011721. PubMed ID: 26798035
[TBL] [Abstract][Full Text] [Related]
20. Differences in Adherence Barriers to Inhaled Medicines between Japanese Patients with Chronic Obstructive Pulmonary Disease and Asthma Evaluated using the "Adherence Starts with Knowledge 20" (ASK-20) Questionnaire.
Toyama T; Kawayama T; Kinoshita T; Imamura Y; Yoshida M; Takahashi K; Fujii K; Higashimoto I; Hoshino T
Intern Med; 2019 Jan; 58(2):175-185. PubMed ID: 30210101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
